{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T08:24:21Z","timestamp":1742804661165},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent evidence suggested that secondary surgical cytoreduction followed by chemotherapy does not result in longer overall survival in patients with platinum-sensitive recurrent ovarian cancer.<\/jats:p><jats:p>This statement is based on a phase III multicenter, randomized clinical trial that lacks a description of the surgical protocol, the surgical technique, and the surgical variables. In a study that evaluates surgical cytoreduction, it is mandatory to assess the grade of cytoreductive surgery achieved (Sugarbaker PH, Langenbeck\u2019s Arch Surg 384:576\u201387, 1999), the extent of disease using PCI (Peritoneal Cancer Index), the technique itself, and the existence of a multidisciplinary approach with extensive upper abdominal procedures in experienced centers (Ren et al, BMC Cancer 15:1-12, 2015). There is evidence proving that the quality of cytoreduction (Al Rawahi et al, Cochrane Database Syst Rev 2013, 2013), the measurement of the amount of disease by PCI (Elzarkaa et al, J Gynecol Oncol 29, 2018), and a multidisciplinary approach with supramesocolic procedures (Ren et al, BMC Cancer 15:1-12, 2015) impact overall survival.<\/jats:p><jats:p>This study fails to compare chemotherapy with secondary cytoreductive surgery since, due to the lack of variables, we can assess neither the performed surgery nor its criteria. This study should not be taken into account to recommend chemotherapy alone over a surgical approach in this group of patients.<\/jats:p>","DOI":"10.1186\/s12957-020-01853-4","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T14:04:10Z","timestamp":1589205850000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Juan Jos\u00e9","family":"Segura-Sampedro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Morales-Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Arjona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Cascales-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"1853_CR1","doi-asserted-by":"publisher","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929\u201339 https:\/\/doi.org\/10.1056\/NEJMoa1902626.","DOI":"10.1056\/NEJMoa1902626"},{"key":"1853_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejso.2018.10.528","volume":"45","author":"Y Wang","year":"2019","unstructured":"Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) versus cytoreductive surgery for ovarian cancer patients: a systematic review and meta-analysis. Eur J Surg Oncol. 2019;45:301\u20139 https:\/\/doi.org\/10.1016\/j.ejso.2018.10.528.","journal-title":"Eur J Surg Oncol"},{"key":"1853_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, SchagenvanLeeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340 https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"key":"1853_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ygyno.2019.01.025","volume":"153","author":"SL Lim","year":"2019","unstructured":"Lim SL, Havrilesky LJ, Habib AS, Secord AA. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019;153:376\u201380 https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.025.","journal-title":"Gynecol Oncol"},{"key":"1853_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004230050246","volume":"384","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbeck's Arch Surg. 1999;384:576\u201387 https:\/\/doi.org\/10.1007\/s004230050246.","journal-title":"Langenbeck's Arch Surg"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/IGC.0000000000000796","volume":"26","author":"AM Angarita","year":"2016","unstructured":"Angarita AM, Stone R, Temkin SM, Levinson K, Fader AN, Tanner EJ. The use of \u201coptimal cytoreduction\u201d nomenclature in ovarian cancer literature. Int J Gynecol Cancer. 2016;26:1421\u20137 https:\/\/doi.org\/10.1097\/IGC.0000000000000796.","journal-title":"Int J Gynecol Cancer"},{"key":"1853_CR7","doi-asserted-by":"publisher","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2013 https:\/\/doi.org\/10.1002\/14651858.CD008765.pub3.","DOI":"10.1002\/14651858.CD008765.pub3"},{"key":"1853_CR8","doi-asserted-by":"publisher","unstructured":"Altman AD, Nelson G, Chu P, Nation J, Ghatage P. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. J Obstet Gynaecol Can 2012;34:558\u2013566. https:\/\/doi.org\/10.1016\/S1701-2163(16)35272-0.","DOI":"10.1016\/S1701-2163"},{"key":"1853_CR9","doi-asserted-by":"publisher","unstructured":"Gurkan D, Ceren Akin A, Sahin H, Aytac Tohma Y, Sahin EA, Gunakan E, et al. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas. J Obstet Gynaecol (Lahore) 2019;0:1\u20137. https:\/\/doi.org\/10.1080\/01443615.2019.1634028.","DOI":"10.1080\/01443615.2019.1634028"},{"key":"1853_CR10","unstructured":"Segura-Sampedro JJ, Morales-Soriano R, Sugarbaker PH. Indicadores Pron\u00f3sticos, Incluyendo la Laparoscopia Diagn\u00f3stica. In: Cascales-Campos P, editor. Citorreducci\u00f3n y quimioterapia perioperatoria en las neoplasias malignas de la superficie peritoneal. Ar\u00e1n Ediciones, 2018, p. 1\u201316."},{"key":"1853_CR11","doi-asserted-by":"publisher","unstructured":"Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29 https:\/\/doi.org\/10.3802\/jgo.2018.29.e47.","DOI":"10.3802\/jgo.2018.29.e47"},{"key":"1853_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/jso.25120","volume":"118","author":"OS Eng","year":"2018","unstructured":"Eng OS, Raoof M, Blakely AM, Yu X, Lee SJ, Han ES, et al. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer. J Surg Oncol. 2018;118:121\u20136 https:\/\/doi.org\/10.1002\/jso.25120.","journal-title":"J Surg Oncol"},{"key":"1853_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1525-1","volume":"15","author":"Y Ren","year":"2015","unstructured":"Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, et al. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer. 2015;15:1\u201312 https:\/\/doi.org\/10.1186\/s12885-015-1525-1.","journal-title":"BMC Cancer"},{"key":"1853_CR14","doi-asserted-by":"publisher","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779\u2013791. https:\/\/doi.org\/10.1016\/S1470-2045(17)30279-6.","DOI":"10.1016\/S1470-2045"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01853-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T23:50:50Z","timestamp":1620690650000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01853-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01853-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"19 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript does not include human participants, human data, or human tissue.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain individual person\u2019s data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}